Quanterix Boosts Growth, Aims for Cash Flow Breakeven

Quanterix reports Q1 2026 earnings with $36.4M revenue, up 20% YoY, but organic growth dips 21%. Instruments lag, but consumables hold steady. They meet $85M cost synergies from Akoya deal, boosting non-GAAP gross margins to 50.9%. CEO Everett Cunningham shifts focus to growth investments, pumping resources into sales, lead gen, and pharma partnerships. Customers praise Quanterix as market leader in ultrasensitive protein tech. End markets feel tough, but pharma is primed for a rebound. Quanterix doubles down on Alzheimers diagnostics, hiring top talent and upgrading HD-X platform for FDA IVD filing. They partner with Tempus AI to integrate LucentAD Complete test into EHR systems. Quanterix aims to hit cash flow breakeven by year-end, balancing research tools profitability with diagnostics upside. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/cb5f758d973d08e7